logo
Five foods that can make you poop

Five foods that can make you poop

News.com.au6 days ago
Stuck in pur-gut-ory?
You're not alone. While chronic stomach issues are worth getting checked out, a bit of bathroom bottleneck from time to time is normal — if not wildly unpleasant.
The good news is that experiencing the anti-runs doesn't require a pharmacy run, as several foods can help clear your colon's traffic jam.
'As a gastroenterologist, I see patients struggle with constipation all the time,' Dr. Mikhail Yakubov of Manhattan Gastroenterology told The Post.
'While medications can help, the most natural first step is often what's on your plate.'
Here are five foods that can gently get things rolling when your gut's on strike.
Kiwis
'Kiwi is a hidden gem when it comes to gut health,' Yakubov said, noting that this fuzzy little fruit is 'rich in both soluble and insoluble fibre, but it also contains an enzyme called actinidin, which may help stimulate digestion.'
According to Yakubov, one or two per day should be sufficient for most people and — as a bonus — it's 'low in sugar and doesn't cause bloating like some other fruits.'
Oatmeal
It's a fan favourite among fitness junkies for a reason.
'Oats are packed with soluble fibre — especially beta-glucan — which helps soften stool by drawing water into the bowel,' he said.
'This makes it easier to pass. A bowl of plain oatmeal in the morning is a great start,' Yakubov added.
A recent study found that eating oatmeal regularly can also help reduce the risk of developing Type 2 diabetes, cardiovascular disease and obesity, so it's an all-round winner.
'Just skip the overly processed flavoured packets, which often have added sugar that can slow motility,' Yakubov suggested.
Chia seeds
'These tiny seeds absorb many times their weight in water, forming a gel-like substance that bulks up and softens stool,' he said. 'They're also rich in omega-3s and fibre.'
Yakubov recommends stirring a tablespoon or two into water, yoghurt or a smoothie for a healthy snack — just make sure to let them sit for at least 10 minutes to give them a chance to fully expand before eating.
Coffee
You're not imagining things — that morning cup of joe really can get things moving. 'It's not just a caffeine jolt; it actually stimulates the muscles of the colon,' he said.
'For some people, it works within minutes of drinking it. A cup in the morning can help jump-start the gut,' he added.
However, Yakubov cautions that too much caffeine can have a dehydrating effect, making constipation worse in the long run, so best to pair your Java with plenty of water.
Cooked spinach
Ah, spinach — you think you've got tons of it until you cook it and it quickly dwindles down to nothing, mostly because it's 90 per cent to 95 per cent water.
That's also part of what makes this nutritional powerhouse so healthy.
'Spinach is a good source of magnesium, which helps draw water into the intestines,' Yakubov said. 'It's also high in fibre and iron — especially important if constipation is linked to anaemia.'
It's the perfect green to pair with your favourite protein.
'A half-cup of cooked spinach adds moisture and fibre to meals,' he said. And it makes for an even smoother ride than a salad.
'Cooked greens are generally easier to digest than raw for people prone to bloating,' he said.
Fun fact: A full bag of fresh spinach (roughly 10 ounces) can cook down to just a cup or less of sauteed greens, so buy two.
So what's the takeaway?
'Most foods that help relieve constipation fall into predictable categories: high-fibre fruits, seeds, leafy greens, whole grains,' he said.
'From a medical standpoint, there's not really a surprising 'magic' food that reliably helps people poop,' Yakubov said.
But if he had to choose?
'I think the best one that fits your answer will be coffee.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Experts warn over risk with commonly used supplement
Experts warn over risk with commonly used supplement

News.com.au

time7 hours ago

  • News.com.au

Experts warn over risk with commonly used supplement

A woman was one step away from going into liver failure after taking a popular supplement. Katie Mohan, 57, started taking 2250mg turmeric supplements after seeing the product spruiked on Instagram as a way to resolve inflammation and joint pain. Turmeric supplements have been used to treat things such as arthritis, joint disorders, allergies, infections and colitis, according to John Hopkins Medicine. With all medications and supplements, there are risks. Weeks after she began taking the pills, she started to notice she was experiencing nausea, fatigue and stomach pain. Her urine had also become a lot darker. It wasn't until the New Jersey woman saw an NBC news report on the growing connection between liver issues and herbal supplements that a light bulb went off for her. The World Health Organisation recommends 0–3 mg per kilogram. For Ms Mohan, that would have been roughly 200mg. Ms Mohan ended up in urgent car where her blood work indicated her liver enzymes were 60 times the normal limit, NBC News reported. Doctors said she was one step away from liver failure and needing a transplant. The Therapeutic Goods Association revealed there had been 18 reports of liver problems experienced by people taking products that featured Curcuma longa (turmeric) or curcumin up until June 29 2023. Nine of these reports had enough information to suggest that the liver injury may have been caused by the curcuma longa or curcumin. Four of these reports had no other ingredients that could have caused issues. The other five cases had other ingredients that may have contributed. There were also several Australian and international case reports about liver injury issues in other countries. Evidence available at the time showed there was a rare risk of liver injury from taking Curcuma longa (turmeric) and/or curcumin in medicinal dosage forms. Risks may be higher for products with enhanced absorption or higher doses. Those with previous liver issues may be more likely to have a reaction. At the time, there were more than 600 medicines listed in the Australian Register of Therapeutic Goods containing the product — many of which can be purchased without a prescription from supermarkets, pharmacies and health food shops.

Health Check: For ASX biotechs, the business of America remains business
Health Check: For ASX biotechs, the business of America remains business

News.com.au

time2 days ago

  • News.com.au

Health Check: For ASX biotechs, the business of America remains business

A slew of medical device makers report good progress in the US Imagion shares almost double on positive FDA feedback Quiet drug developer PYC Therapeutics wins a friend The US healthcare system is mired down by kerfuffles over tariffs, drug pricing and cuts to regulatory and funding bodies, but for ASX biotechs the wheels of decision-making keep grinding. As President Calvin Coolidge (supposedly) said a century ago, 'the business of America is business' and that will never be Trumped. Among a slew of US-related disclosures, Orthocell (ASX:OCC) notes it has pocketed its first US revenue from its flagship nerve repair device, Remplir. The achievement follows Remplir's first surgical use in the US, for a foot repair in Ohio on June 26. The company also cites revenue from 'subsequent early surgical cases in Florida, sourced from the company's network of specialist distributors'. Orthocell's commercial traction comes just three months after the company won US Food and Drug Administration clearance for Remplir, which wraps around peripheral nerves and protects them during surgery. Yesterday Orthocell reported June quarter revenue of $2.73 million, up 22.8% on the record March quarter. This took annual revenue to $9.19 million, up 35.8%. Crucially, that does not include Remplir US revenue. First US revenue for Artrya, too Meanwhile, heart device maker Artrya (ASX:AYA) has announced its first US revenue for its Salix coronary plaque detection platform. This is by way of a US$600,000, five-year contract with the Georgia and Alabama based Tanner Health. Tanner has a network of five hospitals, cardiovascular centres, and 30 physician practices. 'This first revenue represents a major milestone for Artrya as it continues to transition to a revenue-stage business,' the company says. The FDA approved Artrya's device in March. So like Orthocell, it's not wasting any time in monetising the opportunity. Artrya is 'actively progressing' commercial discussions with other US hospital networks. The company is also girding for FDA clearance of a further module. US approval? Imagion that Imagion Biosystems (ASX:IBX) today almost doubled after the company said it had received positive FDA feedback on the company's proposed phase II imaging trial for HER-2 positive breast cancer. The company aims to detect cancers early with its Magsense imaging tech. Magsense combines the use of magnetically detectable nanoparticles with biological agents. The underlying tech, by the way, was created by a Los Alamos, New Mexico physicist called Edward R Flynn. The good doc tinkered with magnetic sensors after his wife contracted breast cancer. The company plans to lodge an Investigative New Drug Application – that is, assent to start a trial – with the FDA in the current quarter. Imagion says the agency provided 'positive feedback and constructive input regarding the study plan and outcomes.' 'I'm very pleased with the trajectory of our communications with the FDA', says Imagion exec chairman Bob Proulx. Investors were pleased as well: the FDA's kind words sent the stock up as much as 92% this morning. Imricor wins Northstar approval Coming back to heart health, Imricor Medical Systems (ASX:IMR) has won European regulatory approval for Northstar, as well as its second-generation ablation catheters and capital equipment. This was under the Continent's European Medical Device Regulation, a more stringent gateway than the old rules. Imricor has developed the world's only MRI-guided ablation catheter, which are single-use consumables. Consisting of a workstation and software, Northstar is key to making the magic happen. In mid-April the European gatekeepers approved the catheters under the old pathway. 'Investments in sales and marketing are beginning to pay dividends, with the number of hospitals in the active European pipeline increasing from seven to 26 over the past six months,' Imricor says. As always, the US presents the biggest market. There, the company has lodged vital documentation with the FDA as part of the Northstar approval process. The company aims to submit all its supportive clinical data by the first half of 2026. 'Approval of Northstar will mark the commercial entry point for Imricor in the US and enable Imricor's sales team to initiate site engagement and pipeline development,' the company says. Mach 7 maintains cruising altitude ProMedicus (ASX:PME) 'mini me' Mach7 Technologies (ASX:M7T) has affirmed its revenue forecast for the year to June 2025, albeit at the lower end of things. Mach 7 also expects to break even. On preliminary unaudited numbers, Mach 7 expects revenue of $33-34 million, in line with guidance of $33-36 million and 15-25% higher than previously. Management expects recurring revenue – subscription revenue and maintenance and support revenue – to be 20% higher. But CARR – contracted annual recurring revenue - should come in at $30-31 million, just below the guided $32-35 million. 'Mach 7 is in a strong financial position with no debt and expects to be operating cash flow positive for the 2024-25 year,' management chirps. Mach 7 provides medical imaging software, including image diagnosis and vendor-neutral image archiving. In crude terms Mach7 is 'same but different' to Pro Medicus – a key commonality being a US focus. But they don't compete directly, by and large. A key difference, of course, is that Mach 7 is worth $80 million, with $22 million of cash backing. Pro Medicus is valued at $33 billion, with its shares surging 140% over the last year. Mach 7 shares have decline 44% over his period. Sniffing a bargain, Mach 7 is lapping up its own shares by way of an ongoing share buyback. Mach 7's new CEO Teri Thomas officially started on July 1 and will update investors on July 29. Thomas headed breast imaging outfit Volpara Technologies, before it was taken over by a South Korean suitor last year. Why we like PYC Drug developer PYC Therapeutics (ASX:PYC) has maintained a low profile and that's partly because of its convoluted story over the years. But the Perth-based PYC now has a clearer focus on a portfolio of four rare disease candidates for rare inherited diseases, across three clinical trials. Growing investor awareness has pushed PYC's market cap to more than $840 million. Broker Bell Potter reckons there's room for more as PYC 'has continued to execute impressively in recent months.' PYC's trials cover the eye diseases retinitis pigmentosa type 11 (RP11) and autosomal dominant optic atrophy (ADOA), as well as polycystic kidney disease (PKD). The most advanced, RP11 is fully recruited should start a registrational phase 2/3 trial in the next six to nine months. This follows recent FDA feedback on trial design. 'Early data has impressed on measurements likely to be primary endpoints in the future registrational trial,' Bell Potter says. The trial would be the first ever pivotal study for RP11, which has no current treatment and affects 1500 to 3500 Americans. Bell Potter values PYC shares at $2.30, a 58% increment on their current value.

Unrecognisable ex-UFC fighter ‘died four times'
Unrecognisable ex-UFC fighter ‘died four times'

News.com.au

time2 days ago

  • News.com.au

Unrecognisable ex-UFC fighter ‘died four times'

Ben Askren revealed he died 'four times' as he fought back the tears in an emotional video statement after undergoing a double lung transplant. The former UFC welterweight was hospitalised last month with a severe case of pneumonia, which reportedly stemmed from a staph infection. Askren was placed in a medically induced coma before successfully having both of his lungs replaced. The former Bellator and ONE Championship welterweight champion is thankfully on the road to recovery, which will be a long and arduous one. UFC 318: Holloway vs Poirier 3 | SUN 20 JULY 12PM AEST | One of the most iconic careers in MMA history will come to a close, as UFC veteran Dustin Poirier makes his final walk to the Octagon | Order Now with Main Event on Kayo Sports. He took to Instagram from his hospital bed on Wednesday to issue an emotional update on his ordeal, which resulted in him losing over three-and-a-half stone (22kg). He said: 'Whenever this is all the way over, I actually just read through my wife's journal cause I don't remember anything from May 28 to July 2. '(I have) no recollection, no idea (of) what happened. We'll kind of go through it all, and I just read through my wife's journal. 'It's like a movie, it's ridiculous. So I only died four times. The ticker stopped for about 20 seconds. 'That's not ideal. I hope you guys know that, but I got the double lung transplant.' Dad-of-three Askren is thankful to have survived the horror ordeal and to see another day. 'I made it out to the other side of it,' he said. 'And I'm gaining quite a bit of strength and learning to use everything again. 'I was actually on a scale yesterday and I was weighing 147 pounds. I haven't been 147 pounds since 15 years old. '(It was) like 50 pounds in a 45-day period. So, man, that was a battle. I don't remember most of it.' The mixed martial arts and wrestling community rallied around the Askren family in their time of need, with UFC president Dana White making a public appeal for donations to the fund set up for his former fighter. A £368,000 ($A680,000) donation from an unknown donor helped Askren receive the lifesaving operation. He said of the support: 'The thing that was most impactful to me was all the love I felt from everybody and it's almost like I got to have my own funeral. 'I still remember it 30 years ago when Dave Phillips died and you listen to all these older people, you know, recollect. '(About) how much they enjoy them, how much they love them. And you know, obviously, he never had to hear that. 'The outpouring of love from the wrestling community was just amazing. It felt so good.' Once he's fully recovered, Askren plans to return to his day job coaching the next generation of wrestlers in Wisconsin. He said: 'I'm more motivated than ever to keep giving and get back and do what I can and help out the best I can help out. 'I love you guys, I appreciate you guys. It's been tough not only on me, but my whole family and my close community. 'So I appreciate everything. I hope you guys appreciate the update. 'And like I said, sometime down the road, maybe Amy and I can detail everything a little more.' The MMA community were overwhelmed to see Askren on his road to recovery, which will be a long one. Former two-weight UFC champion Daniel Cormier commented: 'We love you, buddy. 'You're a fighter, it's why you are fighting back. Thank God we still have you.' Cormier's fellow former two-weight champ Henry Cejudo said: 'Glad you made it through, bro. 'Really put into perspective for all of us. The Funky is back.' New heavyweight champion Tom Aspinall: 'Keep going, Ben. We're all behind you, brother.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store